Audit: QRS - Thymosin Alpha-1 for Health & Longevity

Audit conducted on 08/08/2026 06:09 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	91
Passed	83
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol, time-to-effect, benefit/risk tiers, all 13 monitoring rows and the cadence line trace verbatim to ER lines 397–415, 452, 480–494 and the Benefits/Risks headings.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“No controlled evidence at all”, “No study of dosing time exists”, “all positive studies are in impaired responders”, “No established functional range” mirror the ER.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications retained at full strength; the “never been tested in healthy adults” limitation is preserved in At-A-Glance.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gate items come exclusively from ER Key Interactions & Contraindications; risks from Potential Risks & Side Effects; no modifying factors migrated.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT numbers, author names, or brand names (Zadaxin) appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, non-promotional register matching the ER throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and regimens presented without hedging or alarm.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Descriptive constructions throughout (“Rises most consistently on treatment”, “Screens for autoimmune thyroid disease”).
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives; monitoring targets presented as reference values, not instructions.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No recommending or advising verbs anywhere in the sheet.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns; populations are named in the third person (“people who are not ill”).
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are limited to biomarker names, which cannot be replaced without loss of meaning.
2.8	Information is presented in a concise and very compact manner	🟢	All list items reduced to headings or short noun phrases; no explanatory prose.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no “you”/”your” anywhere in the document.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content centres on self-administered regimens, sourcing quality, and baseline immune workup.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Twice-weekly subcutaneous dosing and a 13-marker laboratory panel are presented without softening.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification toward a mass-market reader.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The under-60 mortality signal and the untested healthy-adult use case are both surfaced prominently.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“longevity-clinic practice” and “immune aging” used; the string “anti-aging” does not occur.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Subcutaneous”, “injection-site reactions”, “immune-related adverse event” used throughout.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings match the template byte-for-byte.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Set comparison against core/qrs/QRS.html returns no missing variable; marker_#_* expanded to 13 rows and qualitative_item_# to 6 items.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Non-variable spans (website="evidence_review", website="audit", website="full_review") are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped into the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard licensed regimen”, “Competing approaches — conventional versus longevity-clinic practice”, “Best time of day” are the ER’s bold labels verbatim; all 13 monitoring row labels match the ER table verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No paraphrase detected in protocol cell labels or monitoring row labels.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji characters in the file; the ER’s “⚠️ Conflicted” markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to headings or short noun phrases; no explanatory prose or duplicated content remains to be cut without violating the completeness requirements of 8.2, 9.2, 14.2 and 15.2.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is echoed in the body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: thymosin_alpha_1_2026-0808-0157_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02, matching the guideline version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0808-0534.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: thymosin_alpha_1_2026-0808-0157_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all twelve keys; no stray whitespace or quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Thymosin Alpha-1 for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Thymosin Alpha-1 for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0808-0534 → 08/08/2026.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header carries only the template subline; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER lines 529–533: what it is, where effects are real, tolerability, open questions.
7.2	[at_a_glance] is no longer than 60 words	🟢	55 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each of the four clauses maps to a distinct sentence in the ER Conclusion.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “signaling molecule from the thymus gland” replaces peptide nomenclature.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial named or numbered.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric results present.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items trace to the ER “Populations who should avoid it” bullet (line 373).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All eight ER-listed populations are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eight discrete <li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER rationales (“for whom no data exist”, “in whom an immune flare … carries disproportionate risk”) were stripped; no dash-trailing clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(especially within 12 months of transplant)”, “(Child-Pugh Class C)”, and the “grade 2 or higher” threshold are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	The ER uses no ranking notation; no bare symbols were carried through.
8.7	If no [stop_items] are present the section is left empty	N/A	Eight stop items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items map one-to-one to the ER interaction bullets at lines 355–371.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	The population-scoped contraindications (transplant recipients, prior grade 2+ irAE) are not duplicated; the drug-class interactions remain distinct as in the ER.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Nine discrete <li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s dash clauses (“— direct antagonism, avoid”, “— mutual blunting, caution”, “— redundant, avoid stacking”) were all stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named drug lists retained for immunosuppressants, corticosteroids, checkpoint inhibitors, interferon/IL-2, live vaccines, NSAIDs/antihistamines, supplements, and thymic peptides; lists trimmed but never dropped.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	All parentheticals are plain comma-separated drug lists; no ranking symbols present.
9.7	If no [caution_items] are present the section is left empty	N/A	Nine caution items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER Therapeutic Protocol lines 397, 401, 405.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Licensed dose/route/duration, the competing longevity-clinic regimen, and dosing time of day are the three decision-relevant aspects for this audience.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine fields populated; “1.6 mg twice weekly”, “450 μg to 1.6 mg daily”, “Evening or morning” all traceable.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Immune markers, hepatitis outcomes, and vaccine antibody responses are the three timeframes given in ER line 452.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Immune markers and hepatitis response are the two High-tier benefits; vaccine response is Medium-tier and placed last.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects are present in the ER; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“3 to 7 days”, “6 to 12 months”, “3 to 6 weeks” with supporting sublines all match ER line 452 and the Benefits section.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides explicit time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All twelve benefit entries correspond to the twelve ER benefit headings.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at the correct tiers.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry reduced to the ER heading; no Magnitude figures carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefit entry.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers have ER content; no span needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eleven risk entries correspond to the eleven ER risk headings.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at the correct tiers.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry reduced to the ER heading; hazard ratios and interaction p-values omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risk entry.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers have ER content; no span needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table rows map to the ER Monitoring Protocol & Defining Success biomarker table (lines 480–494).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 13 ER biomarkers present, with targets reproduced verbatim including “No established functional range” for serum thymosin alpha-1.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Baseline, 4 and 12 weeks, then 6-monthly, plus hepatitis liver-enzyme and symptom-triggered thyroid testing — matches ER lines 476 and 478.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items map to the ER qualitative-marker bullets at lines 498–503.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present, including the expectation-effect caveat item.

Issues 08/08/2026 06:09

Pass rate 100.00%. No issues found.

Issues 08/08/2026 06:06

1. 8.5 — Transplant time window dropped: The first contraindication (QRS line 574) reads “Solid organ transplant recipients on any maintenance immunosuppression” but omits the ER’s time window “particularly within 12 months of transplant” (ER line 373), which item 8.5 requires to be preserved rather than dropped.
2. 2.15 — Colloquial “lab-made” in at-a-glance: [at_a_glance] (QRS line 434) opens with “A lab-made copy”, an informal contraction of the ER Conclusion’s formal “a laboratory-made copy” (ER line 529).

Fixes 08/08/2026 06:06

1. 8.5 — Transplant time window restored: The first contraindication now reads “Solid organ transplant recipients on any maintenance immunosuppression (especially within 12 months of transplant)”, reinstating the time window from ER line 373.
2. 2.15 — Formal term in at-a-glance: Replaced “A lab-made copy” with “A laboratory-made copy” in [at_a_glance], matching the ER Conclusion’s wording.

Issues 08/08/2026 05:58

1. 9.2 — Immunosuppressant interaction omitted: The ER’s first Key Interaction bullet, “Immunosuppressants — direct antagonism, avoid” with its named drug classes (cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, sirolimus, everolimus), does not appear in [caution_items] and is only partially covered by the transplant and autoimmune entries in [stop_items].

Fixes 08/08/2026 05:58

1. 9.2 — Immunosuppressant interaction added: Inserted a new first [caution_items] entry, “Immunosuppressants (cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, sirolimus, everolimus)”, carrying over the ER’s first Key Interaction bullet and its named drug examples.

Issues 08/08/2026 05:45

1. 2.8 / 4.5 — Un-condensed ER prose overruns page: The 13 Monitoring “Why” cells, [monitoring_cadence] (lines 860–865), the six [qualitative_item_#] spans (lines 874–905), and the two-sentence protocol and time-to-effect subs reproduce ER wording at near-full length, so the sheet materially exceeds the one A4 page budget instead of being condensed to it.

Fixes 08/08/2026 05:45

1. 2.8 / 4.5 — Monitoring “Why” column condensed: All 13 “Why” cells were cut from the ER’s full column text to short single-line phrases (e.g., “Detects both the inflammatory tone the compound is meant to reduce and any inflammatory reaction it provokes” → “Inflammatory tone, and any reaction provoked”).
2. 2.8 / 4.5 — Monitoring cadence shortened: [monitoring_cadence] was reduced from the ER’s full paragraph to “Baseline before the first dose; immune and safety panels at 4 and 12 weeks, then every 6 months. Liver enzymes every 4 weeks for 12 weeks in viral hepatitis; thyroid function at any new symptom.”, preserving every timepoint.
3. 2.8 / 4.5 — Qualitative items compressed: All six [qualitative_item_#] spans were trimmed to one rendered line each (e.g., item 6 from “recorded with the explicit caveat that these are the domains most susceptible to expectation effects” to “the domains most susceptible to expectation effects”).
4. 2.8 / 4.5 — Protocol and time-to-effect subs tightened: [action_1_sub], [action_2_sub], [action_3_sub], [time_1_sub], and [time_3_sub] were shortened by removing restated framing while keeping the dose, route, duration, and evidence qualifiers intact.

Issues 08/08/2026 05:42

1. 1.4 / 11.4 — Vaccine time-to-effect sub mismatched: time_3_sub (QRS line 531) carries the ER’s general statement that no subjective effect is expected at any timepoint, which belongs to general immune maintenance rather than to the “Vaccine antibody responses / 3 to 6 weeks” cell it annotates.

Fixes 08/08/2026 05:42

1. 1.4 / 11.4 — Vaccine time-to-effect sub mismatched: Replaced time_3_sub “For general immune maintenance there is no expected subjective effect at any timepoint.” with “Measured as antibody titers when given alongside a vaccine; all positive studies are in populations with clearly impaired responses.”, so the sub now describes the vaccine antibody response cell it annotates (ER lines 189, 191).